Abstract
Wastewater-based epidemiology (WBE) is an emerging approach for community-wide COVID- 19 surveillance. WBE was characterized mostly at large sewersheds such as wastewater treatment plants serving a large population. Although informed public health measures can be implemented in a small population, WBE for neighborhood-scale sewersheds is less studied and not fully understood. This study applied WBE to seven neighborhood-scale sewersheds (average population 1,471) from January to November 2021. Community testing data showed an average of 0.004% incidence rate in these sewersheds (97% of monitoring periods reported two or fewer daily infections). In 92% of sewage samples, SARS-CoV-2 N gene fragments were below the limit of quantification. COVID-19 cases poorly correlated with SARS-CoV-2 N gene concentrations except for one location where frequent COVID-19 testing was required. Thus, we developed a COVID-19 warning system for high COVID-19 risk when the SARS-CoV-2 N gene concentration normalized to pepper mild mottle virus (PMMOV) in wastewater is higher than 10-2. This COVID- 19 warning system now identified neighborhood-scale outbreaks (COVID-19 incidence rate higher than 0.5%) with 73% sensitivity and 71% specificity. Importantly, it can discern neighborhood- level outbreaks that would not otherwise be identified by county-scale WBE. We also demonstrated that SARS-CoV-2 variant-specific RT-qPCR assays could be combined with the COVID-19 warning system to identify the introduction of SARS-CoV-2 variants into sewersheds with a low COVID-19 incidence. This new COVID-19 warning system will contribute to effective community-wide disease surveillance when COVID-19 incidence may be maintained at a low level.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Grainger College of Engineering and the JUMP-ARCHES program of OSF Healthcare in conjunction with the University of Illinois.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used only openly available clinical COVID-19 testing data that were originally located at: https://www.c-uphd.org/covid-case-and-testing-data.html
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
